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Type I interferons, interferon-a and interferon-b, are central
regulators of antiviral immunity and autoimmunity, but little
is known about their role in renal inflammation. Recent work
documents that viral nucleic acids are potent inducers of
interferon-a and interferon-b in mesangial cells and
glomerular endothelial cells. This review discusses the
available evidence on the role of interferon-a and interferon-
b in viral nephropathies, in kidney diseases triggered
by extrarenal infections, in lupus nephritis, and in other
kidney disease entities. Finally, we propose areas of research
that may help unravel the roles of type I interferons and
interferon-related genes in the renal field.
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Fifty years after the discovery of interferon-alpha (IFN-a)
and interferon-beta (IFN-b), which are type I IFNs, renal
science has largely neglected this antiviral cytokine family.1
This is surprising because there are good reasons to study the
role of IFNs in kidney diseases. For example, type I IFNs are
central mediators of antiviral immunity and many types of
kidney diseases are directly or indirectly related to viral
infection (Table 1).2,3 Second, textbooks declare that all cells
can produce type I IFNs during viral infection but respective
data for renal cell populations barely exist. Third, type I IFNs
are central mediators of systemic lupus erythematosus (SLE),
which should include lupus nephritis. Beyond basic science
that may help better understand the pathogenesis of kidney
diseases, additional reasons exist from a clinical point of view.
Recombinant IFNs are approved and efficient drugs in
clinical use, for example, for the treatment of chronic
hepatitis C in renal transplantation or renal cell carcinoma.
As a future perspective, IFN-a-neutralizing antibodies are
now in clinical trials for the treatment of SLE. Thus, its time
for nephrologists and kidney researchers to catch up with the
field of IFN research.
This review provides a short overview on type I IFN
biology and recent data on their expression in renal cells. We
further discuss the potential roles of type I IFN in viral
nephropathies, in kidney diseases triggered by extrarenal
infections, in lupus nephritis, and in other kidney diseases.
Finally, we suggest areas of research that may help unravel the
potential roles of type I IFN in the renal field.
SHORT OVERVIEW ON TYPE I IFN
IFNs are pleiotropic cytokines that have broad effects on
innate and adaptive immunity. The IFN family is divided
into type I and type II IFNs. Type I IFNs include IFN-a, IFN-b,
IFN-o, IFN-t, IFN-d, IFN-k, and IFN-e.4 The predominant
members are the multiple separate protein variants of IFN-a
and a single IFN-b. IFN-g is the only member of type II IFN.4
All type I IFNs bind a common cell-surface receptor, known
as the type I IFN receptor (IFNAR), whereas IFN-g ligates a
different cell-surface receptor, that is, type II IFN receptor.1 A
detailed description of the structural aspects of IFN–IFN
receptor interactions, the IFN signaling pathways, and their
pleiotropic biologic effects have been reviewed elsewhere4–6
and are only briefly outlined in this review. The IFNAR is
composed of two multichain structured distinct subunits,
IFNAR1 and IFNAR2. Each of the receptor subunits interacts
with members of the JAK (Janus-activated kinase) family
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(Figure 1). The IFNAR1 subunit is associated with TYK2
(tyrosine kinase 2), whereas IFNAR2 is associated with JAK1.
In general, the binding of type I IFNs leads to heterodimer-
ization of IFNAR1 and IFNAR2 inducing both autopho-
sphorylation and transphosphorylation of JAK1 and TYK2.
However, the various forms of IFN-a and IFN-b have
different binding affinities to each of the receptor subunits,
which might serve as an explanation for some different
biological effects of IFN-a and IFN-b. This leads to the
activation of signal transducers and activators of transcrip-
tion (STAT)1, STAT2, STAT3, and STAT5, which form
homodimers or heterodimers that translocate to the nucleus.
Further binding of IFN-regulated factor (IRF)9 to the
activated heterodimer of STAT1 and STAT2 forms an
important transcriptional complex known as ISGF (IFN-
stimulated genes factor)3.7 ISGF3 binds to IFN-stimulated
response elements in the promoters of related genes and
initiates transcription.4 Type I IFNs can also induce several
other pathways, for example, STAT1 homodimers stimulate
the transcription of genes containing the IFN-g-activated
sequence.6 Thus, type I IFNs induce different combinations
of STATs to regulate transcription of functionally distinct
genes, but the mechanisms defining such differential STAT
usage and specificity are not well understood. Negative
regulation of type I IFN signaling is mediated by receptor
internalization and degradation, dephosphorylation of JAKs
and STATs by phosphatases, by inducing SOCS (suppressors
of cytokine signaling), and by repression of STAT-mediated
gene activation by PIAS (protein inhibitors of activated
STAT).6
Multiple ISGs contribute to the antiviral activity of type I
IFN. For example, the myxovirus resistance gene is a
guanosine triphosphatase that sequesters viral ribonucleo-
proteins to specific subcellular compartments. 20–50-Oligoa-
denylate synthetases activate ribonuclease-L that degrades
cellular and viral RNA.8 Type I IFNs also modulate innate
and adaptive immune responses and regulate the expression
and function of multiple cytokines. They enhance inter-
leukin-6 signaling and induce chemokines (especially
CXCL10, formerly known as IFN-inducible protein 10),
chemokine receptors, transforming growth factor-b, inter-
leukin-1 receptor antagonist, and soluble tumor necrosis
factor receptors.6 Type I IFNs promote natural killer cell
cytotoxicity, as well as macrophage development, maturation,
and inducible nitric oxide synthase production.7 They also
directly activate immature dendritic cells (DCs) to upregulate
the major histocompatibility complex I and the costimu-
latory molecules CD40, CD80, CD86, which fosters the
presentation of viral (as well as auto) antigens in secondary
lymphoid organs and the priming of antigen-specific T cells.9
Type I IFNs exert potent antiproliferative and proapoptotic
effects on T cells, by inducing cyclin kinase inhibitors and
several proapoptotic molecules (such as Fas/FasL, p53, Bax,
Bak), as well as activation of procaspases 8 and 3.6
Furthermore, type I IFNs regulate the development and
function of B cells. They enhance B cell receptor-dependent
mature B-cell responses and increase survival and resistance
to Fas-mediated apoptosis.6 IFN-a upregulates the expression
of the two major B-cell survival factors, the B lymphocyte
stimulator and the A proliferation-inducing ligand in DCs
and monocytes, a finding that might explain the antiapopto-
tic effect of type I IFNs on B cells. An integrated view shows
that type I IFNs orchestrate antiviral immunity at all levels of
the innate and adaptive immune response, and thereby
contribute to cell death and tissue inflammation as part of
the antiviral host defense.6
WAYS TO INDUCE TYPE I IFN SECRETION
Viral nucleic acids are the most potent inducers of type I IFN
and they are being recognized by two major pathways: the
endosomal Toll-like receptor (TLR) pathway and by cytosolic
sensors (Figure 1). TLR3 detects double-stranded RNA
(dsRNA), for example, from RNA viruses.10 TLR7 and
TLR8 sense single-stranded RNA (ssRNA), as well as viruses
containing ssRNA genomes.11,12 TLR9 in plasmacytoid DCs
and B cells recognizes unmethylated CpG DNA motifs which
are common in bacteria and in some DNA viruses.13 TLR4
recognizes viral proteins at the plasma membrane and
Table 1 | Viral infections that trigger kidney disease
Virus Primary manifestation in the kidney Other possible manifestation in the kidney
Hepatitis C virus Membrano-proliferative GN IgA nephropathy, membranous nephropathy, FSGS, postinfectious
GN, immunotactoid glomerulopathy, fibrillary GN
Hepatitis B virus Membranous nephropathy Mesangioproliferative GN, membrano-proliferative GN, renal vasculitis
HIV Collapsing nephropathy FSGS, mesangioproliferative GN
Parvovirus B19 Tubulointerstitial nephritis Postinfectious GN, FSGS, thrombotic microangiopathy
Polyomaviruses Tubulointerstitial nephritis
Cytomegalovirus Tubulointerstitial nephritis Thrombotic microangiopathy
EBV Acute GN, acute kidney injury
Hantavirus Acute interstitial nephritis Interstitial hemorrhage
Hepatitis A virus Acute kidney injury
Adenovirus Acute interstitial nephritis
Mumps Acute interstitial nephritis
Measles Acute interstitial nephritis
Dengue fever Acute interstitial nephritis
Abbreviations: EBV, Epstein–Barr virus; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; HIV, human immunodeficiency virus.
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activates type I IFN production through the TRIF (Toll/
interleukin (IL)-1 receptor domain-containing adaptor-protein
inducing interferon beta) pathway.14 Recently, it was shown that
TLR2 also recognizes vaccinia virus in an MyD88-dependent
and MyD88-independent manner resulting in type I IFN
release.15 The cytosolic and MyD88-independent pathway that
leads to type I IFN induction is initiated by the caspase
recruitment domain-containing RNA helicases retinoic acid
inducible gene-I (RIG-I) and MDA5 (melanoma differentiation
antigen 5).14 Both helicases induce the production of IFN
through the adaptor protein MAVS (mitochondrial-associated
adaptor protein) (also known as IPS-1, VISA, Cardif). dsRNA
and picornaviruses are detected by MDA5, whereas the
50-triphosphate ends of ssRNA are important for the binding
to RIG-I. Recently, it was discovered that DNA viruses also
trigger IFN through RIG-I as polymerase III converts viral DNA
into 50-triphosphate ssRNA within the cytosol.16 The search for
cytosolic DNA receptors is ongoing. The DNA-dependent
activator of IFN-regulatory factor/DNA sensor Z-DNA binding
protein (ZBP1) has been proposed as one of these receptors.17
IFN induction by viral infections is controlled at the
transcriptional level. The transcription factors IRF3 and IRF7
synergize all upstream receptor pathways. Once being
phosphorylated by the kinases TBK1 and IKKe, they transfer
into the nucleus and locate to IRF-binding elements in IFN-a
and IFN-b promoters.14 Although IRF3 and IRF7 binding is
sufficient to activate IFN-a expression, the induction of IFN-b
also requires nuclear factor-kB binding.18 Secreted IFN-a and
IFN-b act in a paracrine and in an autocrine manner to signal
viral infection by the host. A positive feedback loop is created
because IFNAR activation induces IRF7 and the aforemen-
tioned viral nucleic sensors.6 Interestingly, both plasmacytoid
DCs and conventional DCs differ in terms of their
predominant use of viral sensors. Conventional DCs require
viral replication in the cytosol to activate the cytosolic
helicases and IFN production.19 Hence, conventional DCs
trigger antiviral immunity only when being directly infected
at the tissue level. This mechanism should contribute to viral
nephropathies because the intrarenal DC network comprises
conventional DCs. Plasmacytoid DCs rather localize to the
intravascular compartment and use the TLR system to induce
type I IFN.19 This mechanism allows plasmacytoid DCs to
sense viral infection independent of viral replication. The
endosomal TLRs rather recognize ingested viral particles that
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Figure 1 |Afferent and efferent pathways of IFN signaling. Induction and function of the IFN-a and IFN-b system are regulated by
various pathogen recognition receptors. Activating TLR7 and TLR9 by ssRNA and viral (and bacterial) DNA in intracellular endosomes lead
to the activation of interferon regulatory factor (IRF) 7 in an MyD88-dependent manner. Viral dsRNA stimulation of TLR3 results in the
activation of IRF3 and IRF7 through TRIF. TLR4 signals the binding of endotoxin or viral proteins from the cell surface. Other viral surface
molecules signal through TLR2. The RIG-I-like helicases RIG-I and MDA5 are cytosolic sensors for viral RNA. RIG-I interacts with ssRNA
and dsRNA containing uncapped 50-triphosphate ends. MDA5 is activated by dsRNA in the cytosol. The helicases associate with the
mitochondrial-associated adaptor protein (MAVS), which interacts with the kinases TBK1 and IKKe, leading to the phosphorylation of
IRF3 and IRF7. Viral dsDNA leading to type I interferon production through TBK1 and IRF3 is mediated by DAI and other so-far-unknown
cytosolic DNA sensors. In human cells, RNA-polymerase III can convert cytosolic dsDNA into 50-triphosphate RNA, which induces type I
through RIG-I. Phosphorylation of IRF3 and IRF7 leads to homodimerization and translocation into the nucleus, resulting in the activation
of the transcription of IFN-a genes. Activation of the IKK complex through MyD88 induces NF-kB activity, which induces IFN-b gene
transcription together with the IRF3/IRF7 homodimers. Type I IFN can act in a paracrine and in an autocrine manner. IFN-a and IFN-b
are recognized by the common receptor IFNAR1/2, resulting in the activation of the JAK/STAT1 pathway. The IFN-dependent induction of
IRF7 further autoamplifies IFN signaling and the expression of additional interferon-stimulated genes (ISGs), including 20–50-oligoadenylate
synthetases (OAS) and myxovirus resistance gene (MX). DAI, DNA-dependent activator of IFN-regulatory factor; dsRNA, double-stranded
RNA; IFN, interferon; IFNAR; type I IFN receptor; JAK, Janus-activated kinase; MDA5, melanoma differentiation antigen 5; NFkB, nuclear
factor-kB; ssRNA, single-stranded RNA; RIG-I, retinoic acid inducible gene-I; TLR, Toll-like receptor; TRIF, Toll/interleukin (IL)-1 receptor
domain-containing adaptor-protein inducing interferon beta.
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had reached the circulation. This includes IFN induction
upon the recognition of immune complexes containing viral
nucleic acids. This mechanism is of particular interest in
immune complex nephropathies such as lupus nephritis or
hepatitis C virus-associated glomerulonephritis as discussed
later in this review.
TYPE I IFN SECRETION IN THE KIDNEY
The kidney is a sterile organ, still—similar to other cells—
kidney cells recognize and respond to pathogen-associated
molecular patterns, because they express TLRs and other
recognition molecules in intrarenal DCs and in intrinsic renal
parenchymal cells (reviewed in detail in Anders20). Nucleic
acids are the most potent type I IFN inducers, and among the
TLRs, TLR3 is expressed on intrinsic renal cells and on
intrarenal conventional DCs.20 However, dsRNA induces
IFN-a and IFN-b through TLR3 in DCs but not in mesangial
cells or glomerular endothelial cells.21,22 Interestingly, dsRNA
turned out to be a potent inducer of IFN-a and IFN-b in
these glomerular cells when being transfected into the cytosol
where it ligates RIG-like helicases, that is, RIG-I in
endothelial cells and MDA5 in mesangial cells.21,22
50-Triphosphate RNA induces type I IFNs in mesangial cells
through RIG-I.23 Transfection of dsDNA has the same IFN-
inducing effect but the cytosolic DNA receptors in renal cells
remain obscure.23,24 Type I IFN secretion is associated with a
coordinated induction of4200 ISGs in mesangial cells which
is a consequence of an autocrine-activation loop involving
the IFNAR.21,23 Disrupting this autocrine loop also reduced
the capacity of dsRNA to induce interleukin-6 in mesangial
cells,21 indicating that IFN signaling is generally necessary to
mount the nucleic acid-induced expression of inflammatory
cytokines in mesangial cells.
The immunology literature negates TLR7/8/9 expression
in nonimmune cells,14 but few reports describe their
induction in tubular epithelial cells or podocytes in disease.
The functional contribution of this observation remains
unclear but the dense network of intrarenal conventional
DCs as well as infiltrating macrophages and B cells anyway
assure intrarenal IFN signaling upon activation of these
receptors.25
TYPE I IFN IN VIRAL NEPHROPATHIES
On the basis of the above observations, one would predict
that type I IFN should contribute to the immunopathology
of viral nephropathies when viruses replicate in kidney cells.
Surprisingly, hardly any data are yet available to support this
concept probably because we lack good viral nephropathy
models in rodents. For example, human immunodeficiency
virus (HIV)-1 transgenic mice are used as a model for
HIVAN (human deficiency virus-associated nephropathy),
but this model is based on transgenes encoding for HIV
proteins. Hence, HIV-1 transgenic mice do not represent a
model of viral replication that would be required to study
type I IFN responses to HIV virions. Research with human
renal biopsy samples is especially important in this field. One
study reported increased intrarenal IFN-a production in
human HIVAN biopsies as compared with non-HIV focal-
segmental glomerulosclerosis.26 The local release of IFN-a
should also account for tubuloreticular inclusions,
an ultrastructural hallmark of HIV-infected podocytes
(Figure 2).27 Tubuloreticular inclusions in HIVAN resemble
those seen in blood leukocytes of patients under treatment
with recombinant IFN-a.
Polyomavirus infection of tubular cells in renal allografts
should induce type I IFN expression through polyomavirus
DNA. An appropriate mouse model was established but no
data on the induction or functional role of type I IFN have
yet been reported. Unpublished data from our laboratory
suggest that cytosolic DNA sensors recognize polyomavirus
DNA and induce IFN-a and IFN-b expression in cultured
tubular epithelial cells once the DNA is transfected into the
cytosol similar to mesangial cells or glomerular endothelial
cells.23,24 However, this observation needs to be validated by
replicating BK virus infection in vitro or in vivo. Yet, nothing
is known about the role of endogenous type I IFN during
Hantaan nephropathy. Thus, it is likely that the proinflam-
matory and proapoptotic effects of IFN-a contribute to the
immunopathology of HIVAN, BK nephropathy, or Hantaan
virus infection. Much remains to be discovered about type I
IFN in these viral nephropathies.
TYPE I IFN IN GLOMERULONEPHRITIS THAT IS TRIGGERED BY
EXTRARENAL VIRAL INFECTIONS
Extrarenal viral infections can cause immune complex
glomerulonephritis (Table 1). For example, chronic hepatitis
C virus infection of the liver can trigger membrano-
proliferative glomerulonephritis, a disease in which glomer-
ular deposition of viral particles in immune complexes is
HIVAN LN
Figure 2 |Tubuloreticular structures in glomerular endothelial
cells. Left: The electron microscopy image was acquired from a
renal biopsy specimen of a patient with HIV-associated
nephropathy (HIVAN), original magnification  16,000, kindly
provided by S. Dikman (Department of Pathology, Mt Sinai
Hospital, New York, NY, USA). Right: The electron microscopy
image was acquired from a renal biopsy specimen of a female
patient with lupus nephritis RPA/ISN class IV (original
magnification  16,000, kindly provided by H.-J. Gro¨ne,
Department of Cellular and Molecular Pathology, German Cancer
Research Center, Heidelberg, Germany). Tubuloreticular inclusions
in glomerular cells are indicated by arrows. HIV, human
immunodeficiency virus.
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associated with increased glomerular IFN-a mRNA expres-
sion (our unpublished data in collaboration with Markus
Wo¨rnle and Detlef Schlo¨ndorff). Transient viral infections
also trigger flares of IgA nephropathy, lupus nephritis, or
renal vasculitis. It is believed that this clinical association
refers mainly to a transient immunostimulatory effect on the
production of pathogenic autoantibodies at the DC, B cell, or
plasma cell level.28 Whether type I IFN, among other
cytokine signals, contributes to this transient immune
activation is difficult to assess in patients also because renal
flares manifest after some delay. Some evidence comes from
studies with nephritic mice. Few injections with imiquimod,
a viral ssRNA mimic that ligates TLR7 in DCs and B cells,
aggravated lupus-like immune complex glomerulonephritis
by inducing plasma IFN-a, DNA autoantibody levels, as well
as glomerular IgG and C3 deposition.29 The role of IFN-a
induction in this context is supported by Fairhurst et al.30
who observed aggravation of immune complex glomerulone-
phritis after injecting nephritic B6.Sle123 mice with an
adenovirus expression vector containing a recombinant
IFN-a gene cassette. IFN-a activated DCs, plasma cells, and
T cells, enhanced lymphoproliferation, and aggravated
immune complex glomerulonephritis.30 Interestingly, inject-
ing recombinant IFN-b has opposite effects on lupus
nephritis of MRL(Fas)lpr/lpr mice.31 The divergent effects of
IFN-a and IFN-b on immune complex disease are surprising
because both IFNs act through the same IFNAR.6 However,
the different genetic backgrounds of the mouse models in the
two aforementioned studies compromise firm conclusions.
For example, lack of IFNAR aggravated glomerulonephritis of
MRL(Fas)lpr/lpr mice32 but attenuated four other models of
glomerulonephritis.33–36 Thus, systemic induction of type I
IFNs or confounding gene polymorphisms of IFN signaling
have an impact on experimental immune complex glomer-
ulonephritis.37 Whether these observations predict the role of
type I IFN in glomerulonephritis associated with viral
infections in humans remains to be determined.
ENDOGENOUS TRIGGERS OF TYPE I IFN IN LUPUS NEPHRITIS
Support for this concept is provided by the field of lupus
genetics. Gene polymorphisms that enhance type I IFN
induction or signaling were recently identified as risk factors
for SLE and lupus nephritis.38 In fact, IFN-a is a central
mediator of SLE. Serum IFN-a levels and the expression of
IFN-dependent genes in blood monocytes correlate with SLE
disease activity.39 The same transcriptomic profile of IFN-
dependent genes was found in the glomeruli of patients with
proliferative lupus nephritis.39 Interestingly, endothelial
tubular reticular inclusions are a specific ultrastructural
hallmark of lupus nephritis among the immune complex
glomerulonephritides 40 (Figure 2). Only IFN-a treatment
and viral nephropathies share this finding. What serves as a
trigger for IFN induction in lupus nephritis? Persistent viral
replications, for example, by Epstein–Barr virus or parvovirus
B19, remain under debate as environmental triggers of SLE
and may induce IFN signaling through viral nucleic acid
recognition receptors.28 As a novel concept, endogenous
nucleic acids evolved as inducers of type I IFN, in SLE and
lupus nephritis.41 The similarities between some SLE
manifestations with those of viral infections such as fever,
arthralgia, myalgia, and fatigue should relate to this
mechanism and resemble the side effects of immunotherapy
with recombinant IFN-a.6 Genetic SLE risk factors often
compromise apoptotic cell death and/or clearance of dead
cells which increases the exposure of modified endogenous
nucleic acids to innate viral nucleic acid sensors.42 Self-
nucleic acids activate TLR7 and TLR9,41 but probably not
cytosolic RIG-like helicases as these require viral replication
for IFN induction.19 TLR7 and TLR9 antagonist studies in
various models of murine lupus nephritis further support
this concept43–47 in addition to the aforementioned evidence
coming from IFNAR-deficient lupus mice (Table 2).33–36 The
accumulating evidence for IFN-a as a central cytokine
mediator of SLE raises the question whether IFN-a might
be a valuable therapeutic target and whether IFN-a
Table 2 | Evidence for a role of type I interferons in non-viral kidney disease models
Disease model Experimental tool Main outcome Reference
Serum nephritis (autologous, mouse) IFNAR/ mice GN k Fairhurst et al.49
Injection of IFN-a vector GN m Fairhurst et al.49
Serum nephritis (heterologous, rat) Injection of rec. IFN-b Proteinuria k Satchell et al.51
Lupus nephritis MRLlpr Injection of rec. IFN-b GN k Schwarting et al.31
IFNAR/ mice GN k Hron and Peng32
Injection of TLR7 agonist GN m Pawar et al.29
Injection of TLR7 antagonist GN k Pawar et al.47
Injection of TLR9 agonist GN m Anders et al.52
Injection of TLR9 antagonist GN k Dong et al.43; Lenert et al.44; Patole et al.45
Injection of RIG agonist GN m Allam et al.53
Lupus nephritis B6lpr IFNAR/ mice GN k Braun et al.34
Lupus nephritis NZB IFNAR/ mice GN k Santiago-Raber et al.35
Lupus nephritis NZ/2328 IFNAR/ mice GN k Agrawal et al.33
Pristane-induced lupus IFNAR/ mice GN k Nacionales et al.36
Lupus nephritis B6.Sle123 Injection of IFN-a vector GN m Fairhurst et al.30
Anti-Thy-1.1 (rat) Injection of rec. IFN-b Proteinuria k Satchell et al.51
Puromycin nephropathy (rat) Injection of rec. IFN-b Proteinuria k Satchell et al.51
Post-ischemic ARF IFNAR/ mice Attenuation of ARF See text
Abbreviations: ARF, acute renal failure; GN, glomerulonephritis; IFN, interferon; IFNAR, type I IFN receptor; RIG, retinoic acid inducible gene; TLR, Toll-like receptor.
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antagonism can be used to treat SLE or lupus nephritis. A
first report describes results from a phase I trial that tested an
anti-IFN-a monoclonal antibody in SLE patients.48 Anti-
IFN-a dose dependently inhibited the overexpression of
IFN-inducible genes in whole blood and skin lesions at the
transcript and protein levels.48 It will be interesting to see
whether these readouts predict less SLE disease activity and
renal inflammation.
TYPE I IFN IN OTHER KIDNEY DISEASES
Little information is yet available on the role of IFN-a and
IFN-b in other types of kidney disease (Table 2). Fairhurst
et al.49 discovered that IFN-a4, but not IFN-a5 or IFN-b, was
increasingly expressed by intrinsic renal cells during auto-
logous nephrotoxic serum nephritis and that the amount of
renal IFN-a4 expression correlated with proteinuria and
renal excretoryfunction. The authors speculated this induc-
tion of IFN-a to be functionally relevant because adenoviral
overexpression of IFN-a aggravated nephrotoxic serum
nephritis and the lack of IFNAR abrogated this model.49
Yet, it remains unclear what trigger induced IFN-a4
expression in resident kidney cells in the nephrotoxic serum
nephritis model. Dying cells in necrotic glomerular lesions
might release immunostimulatory nucleic acids during
nephrotoxic serum nephritis, but we recently excluded a role
for TLR3 in this model.50 Satchell et al.51 studied the effects
of recombinant IFN-b injections in three different rat models
of glomerular damage. IFN-b reduced proteinuria in
nephrotoxic serum nephritis of Wistar Kyoto rats, whereas
glomerular pathology and serum creatinine remained mostly
unaffected. A similar result was obtained with Thy-1
nephritis in Lewis rats and puromycin nephropathy in
Wistar rats associated with less podocyte foot process
effacement at the ultrastructural level.51 Satchell et al.
extended their in vivo studies by in vitro work with
glomerular endothelial and podocytes. Recombinant IFN-b
increased the electrical resistance across monolayers of these
cells and decreased albumin permeability. Obviously, IFN-b
can elicit antiproteinuric effects by specifically interacting
with the cells along the glomerular filtration barrier.
Additional evidence for a role of type I IFNs in nonviral
inflammation inside the kidney comes from Freitas et al.54
who used IFNAR-deficient mice to study the role of type I IFN
in post-ischemic acute renal failure. Lack of IFNAR was
associated with attenuation of tubular necrosis, intrarenal
inflammation, and acute renal failure after bilateral renal
pedicle clamping for 45min. These first few studies suggest
that nonviral types of kidney diseases also involve type I IFN
signaling acting in a proinflammatory manner. Thus, IFN-b
may have additional immunoregulatory effects that include,
unexpectedly, antiproteinuric effects at the glomerular filtra-
tion barrier, a phenomenon that deserves further investigation.
SUMMARY AND PERSPECTIVE
Given the many years of IFN research, little is known about
their immunoregulatory role in renal inflammation. First
evidence supports the concept that they contribute to virally
and nonvirally induced types of kidney diseases. IFN
agonists, antagonists, and knockout mice are available and
should represent useful tools for addressing these issues
experimentally. Measuring IFN-a and IFN-b levels in urine
and serum samples, expression studies with human renal
biopsies, as well as gene polymorphism studies on dedicated
kidney disease patient cohorts could further address the
significance of type I IFN signaling in the human kidney in
the future.
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